Electroconvulsive therapy (ECT) is commonly associated with acute hyperdynamic cardiovascular responses, and we hypothesize that intravenous lignocaine can blunt this response. We have measured the effect of lignocaine 1.5 mg/kg IV on heart rate and mean arterial pressure during electroconvulsive therapy. Furthermore, we also assessed seizure duration using both the cuff method and two-lead electroencephalography.
Electroconvulsive therapy (ECT) is commonly associated with acute hyperdynamic cardiovascular responses, including transient hypertension and tachycardia, immediately after the ECT stimulus is delivered. Attenuation or blockade of the acute haemodynamic and myocardial consequences of ECT may be desirable in patients with brain tumours, cardiac conduction defects or ectopy, hypertension, recent myocardial infarction or haemorrhagic stroke, and aortic or cerebral aneurysms 1 . Many drugs, such as nitroglycerine 2,3 , nifedipine 4,5 , betablockers [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] , and clonidine 16 , attenuate the hyperdynamic response to ECT. Recently, we reported that diltiazem 17 and verapamil 18 administered immediately before anaesthesia significantly reduced the increases in peak heart rate and mean arterial blood pressure seen after ECT.
There is controversy whether IV lignocaine blunts acute hyperdynamic responses after ECT. Weinger 12 reported that pretreatment with lignocaine 1.0 mg/kg for ECT produced effects on systolic blood pressure, heart rate, and the rate pressure product similar to those in a control (saline) group. However, they studied only 10 patients. Recently, Fu et al 19 showed that although the duration of seizure activity was decreased in a dose-related fashion after lignocaine pretreatment, the peak increases in blood pressure and heart rate were similar with the lignocaine and saline treatment. We have noted however, that IV lignocaine blunts acute hyperdynamic responses. Moreover, though a controversial issue [20] [21] [22] [23] [24] [25] [26] , IV lignocaine may abolish or attenuate cardiovascular responses to intubation 20, 23, 26 , and we have hypothesized that IV lignocaine can also blunt the hyperdynamic response to ECT. The aim of this study was to re-evaluate the effects of IV lignocaine administration on heart rate, arterial blood pressure and seizure duration during ECT.
METHODS
After obtaining approval from the Institutional Review Board and written informed consent, 25 ASA physical status 2 or 3 patients undergoing ECT treatments for chronic depression were investigated using a randomized, double-blind, placebo-controlled crossover study design. Patients with unstable cardiovascular disease, using beta-adrenergic or calciumchannel blocking drugs, second or third degree atrioventricular block, arrhythmia, hypotension, sinus bradycardia, chronic obstructive pulmonary disease, and renal or hepatic failure were excluded from this study. Each patient received one of two different medications on different days 48 hours apart to allow a washout period; placebo (normal saline) (control group) or lignocaine (lignocaine group). The anaesthesiologists were blinded as to the treatment being administered.
Mean arterial blood pressure (MAP), electrocardiographic data, heart rate (HR), and oxygen saturation (SpO 2 ) values were recorded before the induction of anaesthesia. Tonometric blood pressure was measured with a continuous noninvasive blood pressure-monitoring instrument (BP-508, Colin Corporation, Komaki, Japan) [27] [28] [29] . None of the patients were premedicated.
The control group was given 0.075 ml/kg of saline, and the lignocaine group was given 2% lignocaine, 1.5 mg/kg, and this treatment was conducted one minute before propofol 1.5 mg/kg injection to induce unconsciousness. Before the administration of succinylcholine, a tourniquet applied to the upper arm was inflated to isolate the circulation to the arm and permit accurate motor seizure assessment. Upon loss of consciousness, a blood pressure cuff was applied to isolate the circulation to the arm so as to assess the duration of motor seizure activity (cuff method), and succinylcholine 1.5 mg/kg IV was then administered. Ventilation was assisted via a facemask and oxygen. An electrical stimulus was delivered via bitemporal electrodes using a Sakai CS-1 apparatus (Sakai Medical Instruments, Tokyo, Japan) at a 110 volt setting for seven seconds. The magnitude of the electrical stimulus was held constant during the two ECT treatments conducted on each patient.
HR and MAP were measured before the start of the experiment to establish a baseline and prior to succinylcholine administration, prior to ECT and at the peak response after ECT. The electroencephalographic seizure length was also recorded using a two-channel EEG after the electrical stimulus.
Intragroup comparisons of HR and MAP were performed by two-way ANOVA with repeated measures and paired t-tests with Bonferroni's correction. Between-group comparisons of HR, MAP, and recovery time were made using unpaired t-tests. Between-group comparisons of motor and EEG seizure duration time were made by Mann-Whitney tests. A P value less than 0.05 was considered statistically significant.
RESULTS
The seven men and 18 women completing the study (50 ECT treatments) had an average (mean± SD) age of 59±16 years (range 28-80 y), weight of 54±11 kg (32-68 kg), and height of 158±12 cm (146-181 cm).
There were no significant differences in baseline measures of HR and MAP between the two groups ( Table 1 ).
In the control group, the HR prior to ECT and the peak HR after ECT were significantly higher than the baseline HR (P<0.05 and P<0.01, respectively). In the lignocaine group, the HR prior to succinylcholine, prior to ECT and the peak HR after ECT were significantly more rapid than the baseline HR (P<0.01, 743 respectively). The HR increase after the stimulus was significantly less marked after lignocaine (P<0.01).
LIGNOCAINE AND ELECTROCONVULSIVE THERAPY
In both groups, peak MAP after ECT was significantly higher than the baseline MAP (P<0.01).
Recovery time, indicated by spontaneous respiration, eye-opening and following commands, did not differ significantly between the control and lignocaine groups. Figures 1 and 2 show the motor and EEG durations of seizure activity, respectively.
Motor seizure duration was significantly shorter in the lignocaine group than in the control group (P<0.001) ( Figure 1 ), and EEG seizure duration was also significantly shorter in the lignocaine group than in the control group (P<0.001) ( Figure 2) . No complications potentially related to lignocaine occurred during the current study.
In the control group, ECT was conducted 235.8± 48.9 seconds (mean±SD) after IV saline. In the lignocaine group, ECT was conducted 241.1±46.7 seconds (mean±SD) after IV lignocaine. (These are not significantly different.)
DISCUSSION
This study showed that IV lignocaine 1.5 mg/kg, administered immediately before anaesthesia, significantly reduces the increase in peak HR after ECT. This result is different from that of Weinger et al 12 and Fu et al 19 . However, IV lignocaine did significantly reduce seizure duration as previously reported 12, 19, [30] [31] [32] [33] [34] . Although IV lignocaine is an alternative to other dugs attenuating cardiovascular stimulation during ECT, attention to its marked tendency to shorten seizure duration is essential.
Beta-blockers are generally considered to be the most useful and widely employed drugs for ECT 1 .
McCall and coworkers 8 found that 5 mg and 10 mg doses of labetalol safely and effectively lowered blood pressure and the rate-pressure product (RPP) (but not HR), without shortening seizure duration. Weinger 12 however, showed labetalol to shorten seizure duration. Esmolol also blunted the maximal HR response as well as the blood pressure response 9,10,12,15 (or RPP 9 ). However, esmolol shortened seizure duration 9, 10, 12, 15 . In contrast, there is a report demonstrating that esmolol does not shorten seizure duration 11 . Oral clonidine produced a dose-related decrease in MAP before and after ECT, but produced no significant changes in the duration of either motor or EEG seizure activity, or recovery times after anaesthesia, while clonidine did not significantly prevent change in HR 16 . Furthermore, we recently reported that a 10 mg IV dose of diltiazem, administered immediately before anaesthesia, significantly reduced the increases in peak HR and MAP seen after ECT 17 . However, diltiazem also significantly reduced seizure duration 17 . We also showed that 0.1 mg/kg of verapamil, administered immediately before the anesthesia, significantly reduces the increases in peak HR and MAP after ECT 18 . Moreover, the administration of verapamil did not reduce the duration of the seizure 18 . Though it is difficult to choose the optimal drug for treating hyperdynamic responses after ECT, caffeine 1 are capable of prolonging seizure duration. Thus, administering one of these drugs may be an effective means of achieving premedication prior to ECT.
Lignocaine has been used successfully for many years to control ECT-induced tachyarrhythmias 12, [30] [31] [32] [33] , and in such a case, lignocaine is considered to be advantageous. IV lignocaine significantly reduced the increases in HR after ECT, and the use of IV lignocaine was associated with a remarkably shortened seizure duration.
Swartz 36 commented that the duration of a seizure induced by ECT therapy is routinely taken as an index of efficacy; however, it does not reliably reflect therapeutic impact, probably because seizure duration incompletely describes the amount of seizure activity. It has been generally believed that overall seizure duration is a primary determinant of treatment efficacy, but this view is changing 37 . However, seizure durations of less than 25 seconds are believed to be ineffective 37 . The precise mechanism of therapeutic effect of ECT remains unknown, despite increasing research into this area 37 . We could not determine the mechanism underlying the shortening of seizure duration by lignocaine in this study. As such, we do not know whether shortening of the seizure duration by lignocaine is associated with a reduced therapeutic effect. Therefore further investigation is needed.
In summary, a 1.5 mg/kg IV dose of lignocaine administered before anaesthesia significantly reduced the increases in peak HR seen after ECT. However, lignocaine also significantly decreased seizure duration time. While IV lignocaine is potentially useful for attenuating haemodynamic responses in patients at risk for cardiovascular complications, its effect in reducing seizure duration may interfere with the psychotherapeutic efficacy of ECT. Its use as a routine prophylactic measure may not be recommended for this reason.
